ADVFN Logo
Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
Sharps Technology Inc

Sharps Technology Inc (STSS)

1.85
-0.03
(-1.60%)
At close: December 23 4:00PM
1.85
0.00
( 0.00% )
After Hours: 6:55PM

Empower your portfolio: Real-time discussions and actionable trading ideas.

Key stats and details

Current Price
1.85
Bid
1.84
Ask
1.95
Volume
20,037
1.85 Day's Range 1.9574
1.70 52 Week Range 18.1544
Market Cap
Previous Close
1.88
Open
1.88
Last Trade
1
@
1.95
Last Trade Time
Financial Volume
$ 37,724
VWAP
1.8827
Average Volume (3m)
298,213
Shares Outstanding
1,797,795
Dividend Yield
-
PE Ratio
-0.34
Earnings Per Share (EPS)
-5.47
Revenue
-
Net Profit
-9.84M

About Sharps Technology Inc

Sharps Technology Inc is a medical device company. It offers syringes and other safety products. Sharps provensa ultra-low waste smart safety syringes are designed to eliminate over two million potentially infectious and accidental needlestick injuries. Sharps Technology Inc is a medical device company. It offers syringes and other safety products. Sharps provensa ultra-low waste smart safety syringes are designed to eliminate over two million potentially infectious and accidental needlestick injuries.

Sector
Surgical,med Instr,apparatus
Industry
Surgical,med Instr,apparatus
Headquarters
Sheridan, Wyoming, USA
Founded
-
Sharps Technology Inc is listed in the Surgical,med Instr,apparatus sector of the NASDAQ with ticker STSS. The last closing price for Sharps Technology was $1.88. Over the last year, Sharps Technology shares have traded in a share price range of $ 1.70 to $ 18.1544.

Sharps Technology currently has 1,797,795 shares outstanding. The market capitalization of Sharps Technology is $3.38 million. Sharps Technology has a price to earnings ratio (PE ratio) of -0.34.

STSS Latest News

Sharps Technology’s CEO Issues Shareholder Letter Highlighting Hungary Manufacturing Facility Expansion Plans to Increase SecureGard and SoloGard Product Supply and Revenue

Shareholder letter includes details about the $50+ million sales agreement with a US-based pharma company, plans for Hungary SoloGard manufacturing expansion, and expected delivery scheduleInitial...

Sharps Technology Signs Sales Agreements to Support Major European Healthcare Network and Sells Out Its Inventory for SecureGard

Signed multiple agreements to sell its SecureGard syringe inventory, with initial shipments and revenue commencing in early DecemberAgreements also include new forecasted orders and commitments...

Sharps Regains Nasdaq Listing Compliance

NEW YORK, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (NASDAQ: “STSS” and “STSSW”) (“Sharps”), an innovative medical device and pharmaceutical packaging company offering patented...

Sharps Technology, Inc. Announces Stockholders’ Approval of Reverse Stock Split Ratio and Effective Date

NEW YORK, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (NASDAQ: “STSS” and “STSSW”) ("Sharps"), an innovative medical device and pharmaceutical packaging company offering patented...

Sharps Technology, Inc. Reminds Shareholders to Vote Before Important Shareholder Meeting on October 7, 2024

NEW YORK, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (NASDAQ: STSS) (the “Company”), an innovative medical device and pharmaceutical packaging company offering patented...

Sharps Technology, Inc. Closes $3.5 Million Bridge Financing

NEW YORK, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (NASDAQ: STSS) (the “Company”), an innovative medical device and pharmaceutical packaging company offering patented...

Sharps Technology, Inc. Announces $3.5 Million Bridge Financing

NEW YORK, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (NASDAQ: STSS) (the “Company”), an innovative medical device and pharmaceutical packaging company offering patented...

Sharps Technology Announces Continued Listing on Nasdaq Pending Results of an Upcoming Special Shareholders’ Meeting

NEW YORK, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Sharps Technology, Inc., (NASDAQ: STSS and STSSW) (“Sharps Technology” or the “Company”), an innovative medical device and pharmaceutical packaging...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.21-10.19417475732.062.13991.81524471.98148069CS
4-1.49-44.61077844313.344.16091.74000672.09860722CS
12-1.89-50.53475935833.744.16091.72982132.7204132CS
26-4.079-68.79743632995.9297.4141.716366405.37194362CS
52-7.39-79.97835497849.2418.15441.735207118.71757089CS
156-56.45-96.826758147558.379.641.7168514915.46140241CS
260-56.45-96.826758147558.379.641.7168514915.46140241CS

STSS - Frequently Asked Questions (FAQ)

What is the current Sharps Technology share price?
The current share price of Sharps Technology is $ 1.85
How many Sharps Technology shares are in issue?
Sharps Technology has 1,797,795 shares in issue
What is the market cap of Sharps Technology?
The market capitalisation of Sharps Technology is USD 3.38M
What is the 1 year trading range for Sharps Technology share price?
Sharps Technology has traded in the range of $ 1.70 to $ 18.1544 during the past year
What is the PE ratio of Sharps Technology?
The price to earnings ratio of Sharps Technology is -0.34
What is the reporting currency for Sharps Technology?
Sharps Technology reports financial results in USD
What is the latest annual profit for Sharps Technology?
The latest annual profit of Sharps Technology is USD -9.84M
What is the registered address of Sharps Technology?
The registered address for Sharps Technology is 30 N GOULD STREET, SUITE R, SHERIDAN, WYOMING, 82801
What is the Sharps Technology website address?
The website address for Sharps Technology is www.sharpstechnology.com
Which industry sector does Sharps Technology operate in?
Sharps Technology operates in the SURGICAL,MED INSTR,APPARATUS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
DRCTDirect Digital Holdings Inc
$ 5.25
(854.55%)
68.3M
CHEKCheck Cap Ltd
$ 2.24
(279.66%)
39.96M
SLGLSol Gel Technologies Ltd
$ 1.57
(265.97%)
18.15M
RELIReliance Global Group Inc
$ 3.08
(156.67%)
104.81M
TRAWTraws Pharma Inc
$ 12.50
(149.00%)
27.88M
AILEiLearningEngines Inc
$ 0.199
(-77.51%)
29.6M
MGOLMGO Global Inc
$ 0.4765
(-49.84%)
14.02M
YHCLQR House Inc
$ 1.11
(-36.57%)
1.28M
TNXPTonix Pharmaceuticals Holding Corporation
$ 0.4014
(-34.37%)
191.69M
ADGMAdagio Medical Holdings Inc
$ 1.095
(-33.64%)
4.83M
EDBLEdible Garden AG Inc
$ 0.3669
(54.35%)
409.8M
RGTIRigetti Computing Inc
$ 10.945
(16.81%)
229.28M
TNXPTonix Pharmaceuticals Holding Corporation
$ 0.4014
(-34.37%)
194.75M
NVDANVIDIA Corporation
$ 139.67
(3.69%)
175.84M
RIMEAlgorhythm Holdings Inc
$ 0.0925
(21.07%)
155.72M

STSS Discussion

View Posts
al dean al dean 3 weeks ago
I would think a great demand on their products would result in big uptick in STSS price. Demand that wipes out the inventory is rather rare in my thinking! Thoughts? In at $ 1.80 ,$1.84, and $ 1.91
👍️0
subslover subslover 3 weeks ago
Sells out inventory. Hmmmmmmmm: Sharps Technology Signs Sales Agreements to Support Major European Healthcare Network and Sells Out Its Inventory for SecureGard
Signed multiple agreements to sell its SecureGard syringe inventory, with initial shipments and revenue commencing in early December
Agreements also include new forecasted orders and commitments for all current SecureGard capacity, to begin in Q2 2025
The SecureGard agreements will strengthen the potential revenue curve for the Hungary Operation starting in 2024
NEW YORK, Dec. 05, 2024 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (NASDAQ: “STSS” and “STSSW”), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe products, has begun deliveries of its 1mL and 3mL SecureGard safety syringes under the new sales agreements with a prominent European medical supply company serving Poland, Slovakia, and the Czech Republic. To meet demand in the region, Sharps’ customer has requested additional deliveries by year-end 2024 and committed to purchasing all available plant inventory by Q1 2025.

As a supplier to the largest network of hospitals and outpatient clinics in Central and Eastern Europe, the customer plans to purchase Sharps’ entire existing inventory of 1mL and 3mL SecureGard inventory warehoused in Hungary. This would be followed by new production orders starting in Q2 2025. These orders will consume all currently available SecureGard production capacity of 35 million units at the Hungary manufacturing facility. The customer has also expressed interest in Sharps’ U.S. inventory to fulfill a need for safety syringe supplies in Northern Africa.

The demand for Sharps’ innovative injection solutions continues to grow rapidly, with injectables remaining the preferred delivery method for therapies such as vaccines, biologics, weight loss and maintenance, ophthalmic and cosmetic applications, gene therapies, and diabetes and inflammatory disease management. With increasing levels of interest and potential demand for the Company’s high-quality smart safety syringe products in the region, Sharps is collaborating with both government and private investment sources in Hungary to expand the current manufacturing footprint and take advantage of the need to increase both SecureGard and SoloGard manufacturing capacity. The expansion will be planned to increase the annual SecureGard capacity to more than 100 million units, and the SoloGard capacity to more than 125 million units.

Sharps’ SecureGard and SoloGard product lines focus on low waste and ultra-low waste syringe technologies that also incorporate active safety features to fill the healthcare industry’s demand for the highest quality drug delivery solutions.
👍️0
tw0122 tw0122 3 weeks ago
All inventory sold$$$$ 🚀🚀🚀🚀can we see $2.89- 3.85 profit zone 
👍️0
tw0122 tw0122 3 weeks ago
Stick those needles up $2.73 + 40%! 2m floater
👍️0
Monksdream Monksdream 2 months ago
STSS new 52 week low
👍️0
Monksdream Monksdream 2 months ago
STSS anew 52=week low
👍️0
LOB LOB 5 months ago
Until when did the Nasdaq 180 day exemption give them? R/S could happen ...
👍️0
glenn1919 glenn1919 5 months ago
STSS..........................................https://stockcharts.com/h-sc/ui?s=STSS&p=W&b=5&g=0&id=p86431144783
👍️0
Penny chatter Penny chatter 5 months ago
What's that?
👍️0
Penny chatter Penny chatter 5 months ago
Game! Blouses!
👍️0
Penny chatter Penny chatter 5 months ago
Just loud pipe down
👍️0
peterus peterus 5 months ago
my fist
👍️0
peterus peterus 5 months ago
no but i hate idiots with a big mouth
👍️0
Penny chatter Penny chatter 5 months ago
Shifting here Peter uterus
👍️0
Penny chatter Penny chatter 5 months ago
Who's to and who's bottom?
👍️0
Penny chatter Penny chatter 5 months ago
Must have struck a nerve
👍️0
peterus peterus 5 months ago
give me 1min and you cry for your mamma idiot
👍️0
Penny chatter Penny chatter 5 months ago
Tell your husband I said hi
👍️0
peterus peterus 5 months ago
$$$$$ in the pocket smarty
👍️0
Penny chatter Penny chatter 5 months ago
Large Red shoes red nose
👍️0
Penny chatter Penny chatter 5 months ago
Clowns working overtime solid news and company
👍️0
DOGONE DOGONE 5 months ago
The orders keep coming in...Bound to go up over time.
👍️0
Penny chatter Penny chatter 5 months ago
You're ready?
👍️0
Penny chatter Penny chatter 5 months ago
Nobody
👍️0
TrendTrade2016 TrendTrade2016 5 months ago
down down down
👍️0
Penny chatter Penny chatter 5 months ago
Up up up
👍️0
TrendTrade2016 TrendTrade2016 5 months ago
ouch...now you know who i am...watch and learn
👍️0
Penny chatter Penny chatter 5 months ago
They're trying hard
👍️0
Penny chatter Penny chatter 5 months ago
Faces could melt imo
👍️0
MiamiGent MiamiGent 5 months ago
STSS Sharps Technology Enters Into 5-Year Sales Agreement With Strategic U.S. Medical Products Company Creating +$50M In New Revenue For EU Facility, Definitive Agreement Sells Out The 10mL SoloGard Production Capacity At Sharps' Manufacturing Site
BENZINGA
53 mins ago
Definitive agreement sells out the 10mL SoloGard production capacity at Sharps' manufacturing site in the EU and drives expansion to support the project's growth in the future

Sharps' portfolio of products provides attractive options to the U.S. Pharmaceutical Healthcare Industry as companies look for alternatives to Chinese-manufactured disposable syringes

Sharps has exceeded the product sales commitments for the EU-based facility made to investors in the June 2022 Shareholder Letter

NEW YORK, July 25, 2024 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (STSS.NaE), , an innovative medical device and pharmaceutical packaging company offering patented, best-in-class prefillable and disposable syringe products, has successfully concluded negotiations and signed a contract with a prominent U.S.-based supplier of medical saline and water products to supply them with customized 10mL SoloGard syringes manufactured at Sharps' facility in the EU. The customer initiated an evaluation of Sharps' SoloGard product in light of the recent FDA recalls and tariffs imposed on Chinese supplied syringes. Their successful evaluation of the SoloGard syringes led to the execution of a five-year sales agreement that completely sells out the currently available manufacturing capacity for the 10mL SoloGard product. This transformative syringe program will drive the need for near-term expansion to support the current customer projects slated for the Hungary plant.
👍️0
Penny chatter Penny chatter 5 months ago
Bell about to ring get ready
👍️0
DOGONE DOGONE 5 months ago
Its up from here.
👍️0
Penny chatter Penny chatter 5 months ago
Theater get the popcorn
👍️0
MiamiGent MiamiGent 5 months ago
STSS In just under .34
👍️0
Penny chatter Penny chatter 5 months ago
Slide to the left then slide to the right
👍️0
peterus peterus 5 months ago
yup most of the time he right sold 385s
👍️0
TrendTrade2016 TrendTrade2016 5 months ago
dumpty dumpty two by four...whos running through the bathroom door to puke their bags down the toilet lol
👍️0
Penny chatter Penny chatter 5 months ago
Following papi? Get ready!!
👍️0
subslover subslover 5 months ago
Sharps Technology Enters Into a Five-Year Sales Agreement with Strategic U.S. Medical Products Company Creating +$5O Million in New Revenue for EU Facility
Definitive agreement sells out the 10mL SoloGard production capacity at Sharps’ manufacturing site in the EU and drives expansion to support the project’s growth in the future

Sharps’ portfolio of products provides attractive options to the U.S. Pharmaceutical Healthcare Industry as companies look for alternatives to Chinese-manufactured disposable syringes

Sharps has exceeded the product sales commitments for the EU-based facility made to investors in the June 2022 Shareholder Letter

NEW YORK, July 25, 2024 (GLOBE NEWSWIRE) -- Sharps Technology, Inc., (NASDAQ: “STSS” and “STSSW”), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class prefillable and disposable syringe products, has successfully concluded negotiations and signed a contract with a prominent U.S.-based supplier of medical saline and water products to supply them with customized 10mL SoloGard syringes manufactured at Sharps’ facility in the EU. The customer initiated an evaluation of Sharps’ SoloGard product in light of the recent FDA recalls and tariffs imposed on Chinese supplied syringes. Their successful evaluation of the SoloGard syringes led to the execution of a five-year sales agreement that completely sells out the currently available manufacturing capacity for the 10mL SoloGard product. This transformative syringe program will drive the need for near-term expansion to support the current customer projects slated for the Hungary plant.

“Creating a strategic partnership with the customer and selling out production capacity at the Hungary plant for the next five years is a historic accomplishment for Sharps and the future success of the Company,” stated Robert Hayes, CEO of Sharps Technology. “The collaboration creates a five-year sales agreement for at least 500 million syringes and essentially consumes the current available manufacturing capacity for Sharps’ 10mL SoloGard disposable syringe. This project also provides a clear path for near-term revenue for our company beginning in Q4 2024, with a phased ramp up into 2025.”

Filippo Filippi, General Manager of the SafeGard manufacturing facility, is pleased that his plant is delivering on commitments made by Sharps leadership in 2022. “We have been driven to bring our innovative syringes to the U.S. healthcare market,” says Filippi. “After two years of dedicated efforts, I am excited for this five-year commitment for the 500 million units, starting with the 10mL SoloGard shipments in November of this year. Equally as important, this sales agreement will help provide a solid foundation for the continued expansion of Sharps’ European division in Hungary.”

The Company believes that the need for innovative injection solutions continues to grow rapidly as injectables are the first choice for therapies as diverse as vaccines, biologics, weight loss and maintenance, ophthalmic and cosmetic applications, gene therapies, and diabetes and inflammatory disease management. As a result of this market growth and the impact of the tariffs, recalls, and quality issues with Chinese supplied syringes, Sharps is seeing increasing levels of interest and potential demand for its high-quality smart safety syringe products. Specializing in the development and manufacturing of innovative drug delivery systems, Sharps’ SecureGard and SoloGard product lines focus on low waste and ultra-low waste syringe technologies that also incorporate active safety features, as well as World Health Organization accredited re-use prevention measures.

About Sharps Technology
Sharps Technology is an innovative medical device and pharmaceutical packaging company offering patented, best-in-class smart-safety syringe products to the healthcare industry. The Company’s product lines focus on providing ultra-low waste capabilities, that incorporate syringe technologies that use both passive and active safety features. Sharps also offers products that are designed with specialized copolymer technology to support the prefillable syringe market segment. The Company has a manufacturing facility in Hungary and is partnering with Nephron Pharmaceuticals to expand its manufacturing capacity in the U.S. For more information about Sharps Technology, please visit the website at: http://sharpstechnology.com.

FORWARD-LOOKING STATEMENTS:
This press release contains “forward-looking statements”. Forward-looking statements reflect our current view about future events. When used in this press release, the words “anticipate,” “believe,” “estimate,” “expect,” “future,” “intend,” “plan,” “poised” or the negative of these terms and similar expressions, as they relate to us or our management, identify forward-looking statements. Such statements, include, but are not limited to, statements contained in this press release relating to our business strategy, our future operating results and liquidity, and capital resources outlook. Forward-looking statements are based on our current expectations and assumptions regarding our business, the economy, and other future conditions. Because forward–looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that are difficult t
👍️0
peterus peterus 5 months ago
i know im out
👍️0
TrendTrade2016 TrendTrade2016 5 months ago
teach the clowns a lesson...its a full time job
👍️0
PonkenPlonken PonkenPlonken 5 months ago
you re right, its toast and am out. I only like the 1min staircases and scalped some lunch money.
Happy trading
👍️0
TrendTrade2016 TrendTrade2016 5 months ago
dilute into noise...volume can be deceptive...warrants warrants galore...may 24th 1-a 47 million shares...yikes
👍️0
peterus peterus 5 months ago
dont get burned old man
👍️0
PonkenPlonken PonkenPlonken 5 months ago
my screen shows +15% since we started talking like 2 minutes ago
now enough of this tomfoolery.
👍️0
TrendTrade2016 TrendTrade2016 5 months ago
chase above a top w band can lead to ulcers
👍️0
Penny chatter Penny chatter 5 months ago
Hold on to your undies
👍️0
Penny chatter Penny chatter 5 months ago
Lol
👍️0
TrendTrade2016 TrendTrade2016 5 months ago
top weekly band .37c...weekly chart ugly
👍️0
PonkenPlonken PonkenPlonken 5 months ago
arent you the guy calling yourself "master" and others "son"?
as we speak the stock made a new high
👍️0